ApolipoproteinA1 Assay Kit (APOA1)

For the in vitro quantitative determination of apolipoprotein AⅠ (ApoAⅠ) in serum. For use as an aid if assessing the risk of coronaryartery disease



Product Catalog Number Packaging Method/Format
Product Catalog No: Kit (240 Ml) Pack Size: GB160Z Pack Size: R1: 4×45 ml
R2: 4×15 ml
Pack Size: Immunoturbidimetric
Product Catalog No: Kit (240 Ml) Pack Size: GS161Z Pack Size: R1: 3×60 ml
R2: 3×20 ml
Product Catalog No: Kit (60 Ml) Pack Size: GB160Z/S Pack Size: R1: 1 × 45 ml
R2: 1 × 15 ml
Product Catalog No: Kit (80 Ml) Pack Size: GS161Z/S Pack Size: R1: 1 × 60 ml
R2: 1 × 20 ml
Product Catalog No: Kit (80 Ml) Pack Size: GX161Z/S Pack Size: R1: 1 × 60 ml
R2: 1 × 20 ml
Product Catalog No: Kit (160 Ml) Pack Size: GX161Z Pack Size: R1: 2 × 60 ml
R2: 2 × 20 m
Product Catalog No: Kit (122.4 Ml) Pack Size: GD161Z Pack Size: R1: 24 × 3.8 ml
R2: 12 × 2.6 ml
Product Catalog No: Calibrator Pack Size: GC-Apo A1 Pack Size: 1 × 1 ml
Pack Size:
Pack Size:
Pack Size:

Category:
Product Features

Lipids are metabolised in the intestine or liver, and are transported to tissues and organs after hydrophilic adaptation by a series of micellar structures. These structures consist of an outer monolayer of protein (an apolipoprotein) and polar lipids (phospholipids andunesterified cholesterol) plusan inner core of neutral lipids (triglycerides and cholesterol esters). The apolipoproteins interact with a series of enzymes and tissue receptors and are therefore responsible for further metabolism and catabolismof the micelle. The A apolipoproteins are the main form of protein found in high density lipoproteins (HDL), although chylomicrons are also present. The main role of apolipoprotein AⅠis in the activation of Lecithin cholesterol acyl transferase (LCAT) and removal of free cholesterol from extra-hepatic tissues. Apolipoprotein AⅠmay therefore be described as non-atherogenic, showing an inverse relationship to cardiovascular risk. Studies have shown that there is an inverse relationship between Apo AⅠand coronary artery disease and a direct relationship with Apo B such that patients with CAD have generally reduced levels of Apo AⅠand increased levels of Apo B.

Assay Principle

This method is based on the reaction of a sample containing human Apo AⅠ and specific antiserum to form an insoluble complex which can be measured turbidimetrically at 340nm. By constructing a standard curve from the absorbances of standards the concentration of apo AⅠcan be determined

Order Enquiry

    Order Enquiry Form

    References
    • Bachorik, P.S., Kwiterovich, P.O. Clinica Chimica Acta 1988; 178:1-34
    • Wang, X.L., et al Clin. Chem. 1989; 35(10): 2082-2086
    • Labeur,C., Shepherd. J., Rosseneu, M. Clin. Chem.1990; 36(4):591-597.
    • Adolphson, J.L.,Albers J.J., Journal of Lipid Research 1989; 30:597-606
    • Marcinova, S.M, et al (1992), WHO/IFCC Meeting On Standardisation of Apolipoproteins, May 1992, Nice, France.
    • Albers, J.J, et al (1992) Clin Chem. 38:658.
    • Provisional normal values recalculated on the basis of the CDC values C. Fruchart, J-C. (1986), Ann. Biol. Clin. 44:116.
    • Kukita H., Hiwada K., Kobubu T. SerumApolipoprotein A-1,A-2 and B levels and their discriminative values in relatives of patients with coronary artery disease. Atheroscler 51:261, 1984.
    Enquiry